Radionuclide Or Intended Radionuclide Containing; Adjuvant Or Carrier Compositions; Intermediate Or Preparatory Compositions Patents (Class 424/1.11)
  • Patent number: 11814625
    Abstract: The present disclosure relates generally to the selection of DNA aptamers that prevent aggregation, or fibrilization of alpha-synuclein protein. The aptamers described herein are of use as a therapeutic tool to prevent protein aggregation in neurodegenerative disease.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: November 14, 2023
    Assignee: Carleton University
    Inventors: Maria Cynthia Derosa, Matthew Richard Holahan, Erin Marie McConnell, Katelyn Victoria Ventura, Joshua Parker Callahan, Vernon Harold Daniel Hunt
  • Patent number: 11791080
    Abstract: A superconducting coil of embodiments includes a substrate having a curved surface, a superconducting wire wound on the curved surface, the superconducting wire having a first region and a second region facing the first region, a first resin layer surrounding the superconducting wire and including a plurality of first particles and first resin surrounding the first particles, and a second resin layer positioned between the first region and the second region, the second resin layer covering the first resin layer and including a plurality of second particles and second resin surrounding the second particles and being made of material different from material of the first resin.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: October 17, 2023
    Assignee: Kabushiki Kaisha Toshiba
    Inventors: Mariko Hayashi, Takashi Kuboki
  • Patent number: 11788146
    Abstract: A method for using bodily fluids in determining the cell-specific potency of drugs is provided. A composition comprising a plurality of types of carriers, wherein each carrier comprises a single-cell lethal amount of a therapeutic agent and a unique barcode identifying that agent and wherein the composition comprises equal numbers of each carrier type, equal concentrations of the agent and equal concentrations of each barcode is also provided. Further, methods useful for studying the therapeutic profile of one or more drugs within a cell microenvironment, including but not limited to a tumor, are provided.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: October 17, 2023
    Inventors: Ronen Eavri, Annie Sabbah, Felix Badinter, Raphael Tshuva, Avi Schroeder
  • Patent number: 11771780
    Abstract: A process is provided in which the resulting Fe-tCDTA contrast agent has a reduced osmolality. The process according to the invention comprises the following steps: a) preparing an aqueous solution of tCDTA and FeO(OH), tCDTA and FeO(OH) being present in a molar ratio of from 1:1 to 1:1.4; b) b.1) adjusting a pH of the aqueous solution to between pH 2.5 and pH 4.5 by adding a base, preferably meglumine, and separating the precipitate; or b.2) precipitating the Fe-tCDTA contrast agent from the aqueous solution by adding acetone, separating the precipitate, and preparing an aqueous solution from the precipitate; and c) adjusting a pH of the aqueous solution to between pH 6.5 and pH 8.0 by adding a base, preferably meglumine, and separating the precipitated FeO(OH).
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: October 3, 2023
    Inventors: Eyk Schellenberger, Ralf Hauptmann, Akvile Haeckel, Jing Xie, Joerg Schnorr, Bernd Hamm
  • Patent number: 11771779
    Abstract: The present application provides a compound comprising at least one isotopically labeled nitrogen atom for use in diagnosing a condition or disease in a subject, compositions and kits comprising the compound and methods of using the same.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: October 3, 2023
    Inventors: Ayelet Gamliel, Talia Harris, Gal Sapir, Jacob Sosna, Moshe John Gomori, Rachel Katz-Brull
  • Patent number: 11760823
    Abstract: The invention relates in general to hydrophilic, biocompatible dendronised polymers, to complexes comprising the dendronised polymers, to methods of preparing the dendronised polymer and to uses of the dendronised polymer as a non-viral transfection agent for the delivery of biomolecules, in particular, genome editing tools, into a cell.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: September 19, 2023
    Assignee: The University of Western Australia
    Inventors: Killugudi Swaminatha Iyer, Marck Norret, Jessica Kretzmann, Diwei Ho
  • Patent number: 11744821
    Abstract: Controlled release hydrogel formulations of one or more simvastatin metabolites 3?-hydroxy simvastatin (hSV), 6?-exomethylene simvastatin (eSV), 3?,5?-dihydrodiol simvastatin, 3?,5?-dihydrodiol simvastatin (dSV), simvastatin-beta-hydroxy acid (SVA), and methods for the treatment of patients suffering from injured or degenerating substantially avascular cartilaginous tissue.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: September 5, 2023
    Assignee: University of Cincinnati
    Inventor: Chia-Ying James Lin
  • Patent number: 11746086
    Abstract: Heptamethine cyanine fluorophore conjugates and conjugate precursors are disclosed. Methods of using the conjugates and conjugate precursors are also disclosed. The disclosed conjugates are neutral zwitterionic molecules and exhibit little or no aggregation.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: September 5, 2023
    Assignee: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Martin John Schnermann, Michael Philip Luciano, Roger Rauhauser Nani
  • Patent number: 11738099
    Abstract: A molecular probe comprising a linear peptide that includes an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9; a contrast agent; and a non-peptide linker that covalently links the peptide to the contrast agent.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: August 29, 2023
    Inventors: Zheng-Rong Lu, Zheng Han
  • Patent number: 11738095
    Abstract: This invention relates generally to cyanine-containing compounds; pharmaceutical compositions comprising cyanine-containing compounds; and methods of using cyanine-containing compounds for cancer cell imaging, cancer cell growth inhibition, and detecting cancer cells, for example. Compounds of the invention are preferentially taken up by cancer cells as compared to normal cells. This allows many uses in the cancer treatment, diagnosis, tracking and imaging fields.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: August 29, 2023
    Assignee: Emory University
    Inventors: Leland W. K. Chung, Lucjan Strekowski, Chunmeng Shi, Maged Henary, Gabor Patonay, James J. Krutak, Xiaojian Yang, Guodong Zhu, Ruoxiang Wang, Haiyen E. Zhau
  • Patent number: 11723992
    Abstract: Disclosed herein are methods preparing a purified, carrier-free 68Ga solution. Tire present disclosure also provides systems for preparing a purified, carrier-free 68Ga solution. The present disclosure also provides compositions comprising the purified, carrier-free 68Ga solutions disclosed herein. Also provided are methods of administering compositions of the present disclosure to a patient in need thereof, for example, for imaging a disease or disorder, such as cancer.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: August 15, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Mai Lin, Carlos E. Gonzalez-Lepera
  • Patent number: 11718625
    Abstract: The present disclosure relates to the fields of near-infrared surgical navigation fluorescent molecules, cell marker imaging and so on, and in particular discloses an active targeting near-infrared fluorescent small molecule structure and a preparation method thereof. The present disclosure prepares the active targeting near-infrared fluorescent small molecule with pemetrexed disodium and derivatives thereof as active targeting groups by utilizing an organic total synthesis method. Such active targeting near-infrared fluorescent molecule has the advantages of high active targeting property, strong specificity, good water solubility, high fluorescence quantum yield and so on.
    Type: Grant
    Filed: November 27, 2020
    Date of Patent: August 8, 2023
    Inventors: Huiming Cai, Yiqing Wang
  • Patent number: 11712485
    Abstract: Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: August 1, 2023
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Craig Zimmerman, John L. Joyal, Genliang Lu
  • Patent number: 11713305
    Abstract: In some aspects, the present disclosure provides gadolinium based sensors which may be used to image zinc ions in vivo. In some embodiments, the compounds show appropriate reactivity with zinc ions while maintaining high relaxivity to achieve improved background relative to other sensors.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: August 1, 2023
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Andre F. Martins, Sara Chirayil, Maria Veronica Clavijo Jordan, A. Dean Sherry
  • Patent number: 11684681
    Abstract: Disclosed are methods of detecting eosinophil degranulation in the respiratory tract of subjects. Also, disclosed are methods of producing medical images of the respiratory tract of subjects. The method can include administering radiolabeled heparin to the respiratory tract of subjects, wherein the radiolabeled heparin binds to one or more eosinophil granule protein in the mucosal tissue of the respiratory tract.
    Type: Grant
    Filed: July 19, 2021
    Date of Patent: June 27, 2023
    Inventors: Leonard F. Pease, Hedieh Saffari, Gerald J. Gleich, Kristin M. Leiferman, Kathryn A. Peterson, Russell Morris Condie
  • Patent number: 11680105
    Abstract: The present invention relates to diagnostic and therapeutic agents comprising recombinant antibody fragments to bind a protein associated with cancer and methods of use of these diagnostic and therapeutic agents.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: June 20, 2023
    Inventors: Jayanth Panyam, Stephen Kalscheuer, Vidhi D. Khanna
  • Patent number: 11672797
    Abstract: The present invention relates to methods of treating or inhibiting keloids in a subject with hypoxia-inducible factor-1 (HIF-1) inhibiting compounds, methods of screening or identifying compounds to induce cell death in keloids, and methods of inducing cell death in keloids.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: June 13, 2023
    Assignee: Hampton University
    Inventors: Joanne Chan, Jessica L. Richert
  • Patent number: 11666671
    Abstract: A molecular imaging agent including a detectable moiety, a chelation moiety, and a carrier moiety is provided. In one embodiment, the detectable moiety is coupled to the chelation moiety and the chelation moiety is linked to the carrier moiety. In another embodiment, the detectable moiety is 99mTc; the chelation moiety includes HYNIC; and the carrier moiety includes from N-terminus to C-terminus: a His6 purification tag, a human VEGFA polybasic tag sequence, and a human Fc stabilization segment.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: June 6, 2023
    Assignee: Northwestern University
    Inventor: Jing Jin
  • Patent number: 11654203
    Abstract: Disclosed herein are a dual-targeted carbonic anhydrase IX complex, a contrast agent comprising the same, and a synthesizing method thereof. The dual-targeted carbonic anhydrase IX complex includes a carbonic anhydrase IX (CA9) binding peptide, a sulfonamide derivative, and a metal chelating agent. The dual-targeted carbonic anhydrase IX complex has potential for use as a molecular nuclear drug.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: May 23, 2023
    Inventors: Siao-Syun Guan, Tsai-Yueh Luo, Tse-Zung Liao, Cheng-Liang Peng, Kun-Liang Lin
  • Patent number: 11642418
    Abstract: Disclosed is the use of a radiolabeled anti-nanobody in the prognosis and diagnosis of cancers. In particular, disclosed is an immunoconjugate for detecting a PD-L1 molecule. The immunoconjugate comprises the VHH chain of a specific anti-PD-L1 nanobody and a radionuclide, and can be used for non-invasive detecting of expression of the object PD-L1 to be detected. The immunoconjugate of the invention has small size and high specificity, and is suitable for systemic detection which simultaneously targets primary and metastatic tumors, and has high accuracy and low radiation dose.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: May 9, 2023
    Inventors: Hong Hoi Ting, Chung Lim Wong
  • Patent number: 11638763
    Abstract: Embodiments of the present disclosure provide a nanoparticle based platform, and nanoallergens for identifying, evaluating and studying allergen mimotopes as multiple copies of a single mimotope or various combinations on the same particle. The nanoparticle is extremely versatile and allows multivalent binding to IgEs specific to a variety of mimotopes, simulating allergen proteins. Nanoparticles can include various molecular ratios of components. For example, the nanoallergens can include about 0.1-40% mimotope-lipid conjugate and about 60-99.9% lipid. The mimotope-lipid conjugate includes a mimotope, a first linker, and lipid molecule. Nanoallergens can be used in in vitro and in vivo applications to identify a specific patient's sensitivity to a set of epitopes and predict a symptomatic clinical response, identify allergen epitopes through blind screening peptide sequences from allergen protein, and in a clinical application similar to a scratch test.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: May 2, 2023
    Assignee: University of Notre Dame du Lac
    Inventors: Zihni Basar Bilgicer, Peter Edward Deak, Tanyel Kiziltepe Bilgicer, Jared Francis Stefanick, Jonathan Darryl Ashley
  • Patent number: 11628229
    Abstract: A method for preparing 18F radiolabeled biomolecules and agents for 18F-PET imaging is disclosed herein. A perfluoroaryl-conjugated target tracer is synthesized and purified with temperature and solvent conditions that are mild for the tracer molecule. The purified perfluoroaryl-conjugated target tracer is then labeled with 18F using 18F salts within a short reaction time, and with temperature and solvent conditions that are mild for the tracer molecule. The method provides a quick and convenient process that maintains the biological activities of the target molecules. The radio-labeled biomolecules may be used as contrast agents for Positron Emission Tomography (PET).
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: April 18, 2023
    Inventors: Mark D. Pagel, Iman Daryaei, Abigail Shepard
  • Patent number: 11612164
    Abstract: Drift reduction adjuvant composition and agricultural sprays containing such agricultural compositions contain water, a Newtonian responding polymer such as guar gum, an emulsifier such as a polyoxyethylene sorbitan emulsifier, and an oil. When the agricultural spray containing the drift reduction adjuvant composition and a pesticide is delivered from an agricultural nozzle, it produces fewer droplets less than 150 ?m in diameter and either reduces, maintains or increases (e.g., by up to 30 percentage points) the number of ultra-coarse droplets above 622 ?m in diameter compared to an agricultural spray of the pesticide without the drift reduction adjuvant composition sprayed under the same conditions.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: March 28, 2023
    Assignee: WinField Solutions, LLC
    Inventors: Daniel C. Bissell, Danny Brown
  • Patent number: 11607465
    Abstract: This invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: March 21, 2023
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Gabriela Chiosis, Naga Vara Kishore Pillarsetty, Jason S. Lewis, Steven M. Larson, Tony Taldone, Mary L. Alpaugh, Erica M. Gomes-DaGama
  • Patent number: 11576927
    Abstract: A method of treating a chronic wound may comprise applying to the wound a first scaffold comprising an electrospun polymer fiber. The electrospun fiber may comprise a polymer selected from the group consisting of polyglycolic acid, poly(lactide-co-caprolactone), polylactic acid, polycaprolactone, copolymers thereof, and combinations thereof. The first scaffold may have a thickness from about 50 ?m to about 1 mm, a length from about 1 cm to about 20 cm, and a width from about 1 cm to about 15 cm. The method may further comprise keeping the first scaffold on the chronic wound for a time period of about 3 days to about 21 days. After the time period passes, the chronic wound may have a decreased planimetric area.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: February 14, 2023
    Assignee: Nanofiber Solutions, LLC
    Inventors: Jason Chakroff, Ronald Lloyd Bracken, Jed Johnson
  • Patent number: 11576987
    Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I: T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula I.
    Type: Grant
    Filed: October 21, 2021
    Date of Patent: February 14, 2023
    Inventors: Michael K. Schultz, Frances L. Johnson, Somya Kapoor, Dongyoul Lee, Mengshi Li, Molly Martin
  • Patent number: 11565002
    Abstract: Provided herein are imaging agents, antidotes to the imaging agents and methods of using the same to image a thrombus or blood clot or thrombin including sites of thrombin accumulation and to diagnose and treat thrombosis. The imaging agents include an aptamer capable of binding the thrombus or thrombin in particular linked to a reporter moiety. The imaging agents may be used to label the thrombus or sites of thrombin accumulation. Antidotes capable of binding to the aptamer in the imaging agent are also provided. The antidotes may further be linked to a quencher capable of quenching the reporter moiety.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: January 31, 2023
    Assignee: Duke University
    Inventors: Bruce A. Sullenger, Kady-Ann C. Steen-Burrell, Bethany Powell Gray
  • Patent number: 11541133
    Abstract: A cancer targeting composition, kit, and method for treatment of cancer cells overexpressing somatostatin receptors is disclosed. The composition includes a radioisotope, a chelator, and a targeting moiety. The chelator includes a nitrogen ring structure including a tetraazacyclododecane, a triazacyclononane, and/or a tetraazabicyclo [6.6.2] hexadecane derivative. The targeting moiety includes a somatostatin receptor targeting peptide. The somatostatin receptor targeting peptide includes an octreotide derivative. The targeting moiety is chelated to the radioisotope by the chelator whereby the cancer cells are targeted for elimination.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: January 3, 2023
    Inventors: Izabela Tworowska, Nilesh Wagh, Ebrahim S. Delpassand, Federico Rojas-Quijano, Paul Jurek, Garry E. Kiefer, Tania A. Stallons, Amal Saidi, Julien Torgue
  • Patent number: 11534114
    Abstract: The present invention provides 18F-labeled amino acids or derivatives thereof having formula (I) and methods of making same, which can be suitable for PET imaging:
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: December 27, 2022
    Assignee: Simon Fraser University
    Inventors: Paul Schaffer, Hua Yang, Robert Britton, Matthew Nodwell, Zheliang Yuan
  • Patent number: 11532406
    Abstract: Embodiments of the invention provide methods of synthesizing 18F-tetrafluoroborate (18F-TFB) via direct radiofluorination on boron trifluoride (BF3) to enhance both labeling yield and specific activity. Uses of 18F-TFB are also contemplated.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: December 20, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Timothy R. DeGrado, Huailei Jiang
  • Patent number: 11511001
    Abstract: Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: November 29, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Marcus Kelly, Dangshe Ma, William Olson, Gavin Thurston, Richard Tavare
  • Patent number: 11497809
    Abstract: Disclosed herein are multifunctional nanoparticle compositions. The compositions can be useful for the treatment of cancer by enhancing the anti-tumor effectiveness of radiation directed to a tissue, cell or a tumor and the methods of use thereof. The multifunctional nanoparticle composition comprises a metal oxide nanoparticle core; a functional coating on the surface of the metal oxide nanoparticle core; and a matrix carrier in which the coated nanoparticle is embedded.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: November 15, 2022
    Inventors: Xiaoyu Wu, Claudia Regina Gordijo, Azhar Z. Abbasi, Preethy Prasad, Mohammad Ali Amini
  • Patent number: 11497821
    Abstract: The present disclosure relates to a method for labeling a biomolecule, a fluorescent dye, or a nanoparticle compound with a radioisotope, comprising: (a) providing a cyclooctyne compound represented by the following formula (I) comprising the biomolecule, the fluorescent dye, or the nanoparticle compound which is bound to a cyclooctyne moiety of the cyclooctyne compound; and (b) reacting the cyclooctyne compound of formula (I) with a quinone compound represented by the following formula (II) to give a biomolecule, a fluorescent dye, or a nanoparticle compound labeled with the radioisotope: in formula (I), (Z is the biomolecule, the fluorescent dye, or the nanoparticle compound) in formula (II), (b is 0 or an integer from 1 to 10; L is CH2, —COO—, or —CONH—; M is the radioisotope).
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: November 15, 2022
    Assignee: Korea Atomic Energy Research Institute
    Inventors: Sang Hyun Park, Sajid Mushtaq, Dae Seong Choi
  • Patent number: 11485758
    Abstract: The present invention provides bi-terminal PEGylated peptide conjugates that target an integrin such as ?v?6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the PEG moieties. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating integrin-mediated diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, chronic fibrosis, chronic obstructive pulmonary disease (COPD), lung emphysema, and chronic wounding skin disease. Compositions and kits containing the peptide conjugates of the present invention find utility in a wide range of applications including, e.g., in vivo imaging and immunotherapy.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: November 1, 2022
    Assignee: The Regents of the University of California
    Inventors: Sven H. Hausner, Julie L. Sutcliffe
  • Patent number: 11471463
    Abstract: The present invention is drawn to the use of the compounds highlighted in Tables 1 & 2 and analogs thereof, for enhancing IR-mediated cellular cannibalism in cancer cells. Said compounds are herein called “enhancers of IR-mediated cellular cannibalism”. They can be used to enhance tumor immunogenicity and/or to induce a significant protective anticancer immune response in subjects that will receive or that have received a radiotherapy treatment. In other words, said compounds can be used to potentiate a radiotherapy treatment in a subject in need thereof. Said compounds are preferably chosen in the group consisting of: Mebhydroline 1,5-napthalene disulfonate salt, Flurbiprofen, Minaprine dihydrochloride, Myricetin, Digoxin, Digitoxin, Lanatoside, LOPA87, VP331, RN-1-026, SG6163F, VP450, and VP43.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: October 18, 2022
    Assignee: Institut Gustave Roussy
    Inventors: Jean Luc Perfettini, Eric Deutsch, Catherine Brenner, Jean-Christophe Cintrat, Frederic Taran
  • Patent number: 11458205
    Abstract: Provided herein are conjugates including a polypeptide and one or more drug molecules. The polypeptide includes one or more charged motifs, and may further include one or more uncharged motifs. The conjugates may be used to effectively deliver the drug molecule to a subject.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: October 4, 2022
    Assignee: Duke University
    Inventors: Ashutosh Chilkoti, Samagya Banskota, Parisa Yousefpour, Jayanta Bhattacharyya
  • Patent number: 11453721
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16, such as ovarian tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: September 27, 2022
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Lauric Haber, George D. Yancopoulos, Alison Crawford
  • Patent number: 11433023
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: September 6, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 11426487
    Abstract: The present invention relates to implants comprising a deformable body formed of a polymer comprising functional groups capable of cross-linking to form a cross-link; said body provided in a first configuration which is cross-linked to a second configuration upon application of a selected stimuli; wherein said selected stimuli causes said cross-linking of said functional groups.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: August 30, 2022
    Assignee: SetBone Medical Ltd.
    Inventors: Nimrod Kaufmann, Royi Kaufmann
  • Patent number: 11419954
    Abstract: Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: August 23, 2022
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Jenny Jie Yang, Fan Pu, Shenghui Xue, Jingjuan Qiao, Shanshan Tan, Mani Salarian
  • Patent number: 11419934
    Abstract: Methods for producing an anti-tumor effect in a subject suffering from a cancer or a tumor are disclosed. The methods comprise administering to the patient a Vascular Disrupting Agent (VDA) that a combretastatin agent and one or more antibodies selected from the group consisting of: a CTLA-4 antibody, a PD-1 antibody, a PD-L1 antibody, and a PD-L2 antibody in amounts effective therefor. Examples of combretastatin include CA1P, CA4P, and their corresponding salts and prodrugs. The combination of the VDA and one or more of the antibodies produced a synergistic anti-tumor effect.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: August 23, 2022
    Assignee: Oncotelic Therapeutics, Inc.
    Inventors: David J. Chaplin, Kimberly Perkins
  • Patent number: 11414455
    Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: August 16, 2022
    Inventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
  • Patent number: 11413359
    Abstract: The present invention provides compounds that have motifs that target the compounds to cells that express integrins. In particular, the compounds have peptides with one or more RD motifs conjugated to an agent selected from an imaging agent and a targeting agent. The compounds may be used to detect, monitor and treat a variety of disorders mediated by integrins.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: August 16, 2022
    Inventors: Samuel Achilefu, Kexian Liang, Rui Tang
  • Patent number: 11406720
    Abstract: The present disclosure relates to Fibroblast Growth Factor Receptor 2-specific peptide reagents, methods for detecting epithelial-derived cancer cells such as esophageal, colorectal, gastric, pancreatic or breast carcinoma cells using the peptide reagents, and methods for targeting such cells using the peptide reagents.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: August 9, 2022
    Inventors: Thomas D. Wang, Juan Zhou
  • Patent number: 11406724
    Abstract: Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radio-therapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: August 9, 2022
    Inventors: Kaushik J. Dave, Shubh D. Sharma
  • Patent number: 11365219
    Abstract: Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R1, L1, L2, G, M, Y1Y2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: June 21, 2022
    Inventors: James R. Heath, Rosemary Dyane Rohde, Arundhati Nag, Samir Das, Aiko Umeda
  • Patent number: 11358982
    Abstract: Provided herein are methods for iodinating biomolecules, including proteins and peptides. The methods can be used to successfully and efficiently iodinate biomolecules under relatively mild reaction conditions. As a consequence, the methods described herein can be used to iodinate biomolecules that include, for example, an oxidatively unstable moiety (e.g., an optical dye) without adversely impacting the oxidatively unstable moiety.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: June 14, 2022
    Assignee: Ohio State Innovation Foundation
    Inventor: Krishan Kumar
  • Patent number: 11358962
    Abstract: The invention relates to small molecule imaging tools, specifically compounds of formula II and to pharmaceutically acceptable acid addition salts thereof, wherein R1-R6 have any of the values defined in the specification.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: June 14, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Edilio Borroni, Luca Gobbi, Michael Honer, Henner Knust, Matthias Koerner, Dieter Muri
  • Patent number: 11357874
    Abstract: Methods and compositions for treating, diagnosing and staging cancers, in particular overexpressing the Human Epidermal growth factor Receptor 2 protein (HER2+) given rise to in breast, gastric, gastroesophageal, ovarian, pancreatic cancer and brain tumors, which may be metastatic to the brain or other site. More specifically, the invention provides for Targeted Radionuclide Therapy (TRNT) with a compound of the invention having a peptide that targets the HER2+ cells, a second component for combining metals into complexes through a ring structure (DOTA), and a third radioisotope component, Lu-177 and Ga-68, in which embodiments further include a companion diagnostic, and in which embodiments further include anti-integrin precision medicines for cancers expressing ?v?3 and ?v?5 integrins, HER2+, vascular endothelial growth factor, vitronectin, fibronectin, tenascin, reelin, kindlin and talin.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: June 14, 2022
    Inventor: Stanley Satz
  • Patent number: 11344639
    Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: May 31, 2022
    Inventors: Paul E. Morin, David Donnelly, Dasa Lipovsek, Jochem Gokemeijer, Maria Jure-Kunkel, David Fabrizio, Martin C. Wright, Douglas Dischino, Samuel J. Bonacorsi, Jr., Ralph Adam Smith, Virginie Lafont, Daniel Cohen, David K. Leung